Atul R Mahableshwarkar

Summary

Publications

  1. doi request reprint A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
    Atul R Mahableshwarkar
    CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA
    Psychopharmacology (Berl) 232:2061-70. 2015
  2. doi request reprint A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
    Atul R Mahableshwarkar
    Takeda Global Research and Development Center, One Takeda Parkway, Deerfield, IL 60015, USA
    Curr Med Res Opin 29:217-26. 2013
  3. pmc Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Mohammed Y Alam
    aAmerican Medical Research Inc, Oak Brook bTakeda Development Center Americas, Deerfield, Illinois, USA
    Int Clin Psychopharmacol 29:36-44. 2014
  4. doi request reprint A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder
    Atul R Mahableshwarkar
    CNS Medicine, Takeda Development Center Americas, Deerfield, Illinois
    J Clin Psychiatry 76:583-91. 2015
  5. doi request reprint A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder
    Paula L Jacobsen
    Takeda Development Center Americas, Deerfield, Illinois
    J Clin Psychiatry 76:575-82. 2015
  6. doi request reprint Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
    Paula L Jacobsen
    Takeda Development Center Americas, Deerfield, IL, USA
    J Sex Med 12:2036-48. 2015
  7. doi request reprint A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
    Atul R Mahableshwarkar
    Takeda Development Center Americas, Deerfield, Illinois, USA
    Hum Psychopharmacol 29:64-72. 2014
  8. doi request reprint Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Paula L Jacobsen
    aTakeda Development Center Americas Inc, Deerfield, Illinois bCNS Healthcare, Orlando, Florida, USA
    Int Clin Psychopharmacol 30:255-64. 2015
  9. doi request reprint A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
    Atul R Mahableshwarkar
    Takeda Development Center Americas, Deerfield, IL, USA
    Neuropsychopharmacology 40:2025-37. 2015

Collaborators

  • Richard S E Keefe
  • John Zajecka
  • Paula L Jacobsen
  • Serena Chan
  • Lambros Chrones
  • Yinzhong Chen
  • Michael Serenko
  • Mohammed Y Alam
  • Madhukar H Trivedi
  • Anita H Clayton
  • Linda Harper

Detail Information

Publications9

  1. doi request reprint A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
    Atul R Mahableshwarkar
    CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA
    Psychopharmacology (Berl) 232:2061-70. 2015
    ..Vortioxetine has reduced depressive symptoms in adults with major depressive disorder (MDD) in multiple clinical trials...
  2. doi request reprint A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
    Atul R Mahableshwarkar
    Takeda Global Research and Development Center, One Takeda Parkway, Deerfield, IL 60015, USA
    Curr Med Res Opin 29:217-26. 2013
    ..This trial assessed the efficacy and tolerability of 2.5 and 5 mg vortioxetine for the treatment of MDD...
  3. pmc Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Mohammed Y Alam
    aAmerican Medical Research Inc, Oak Brook bTakeda Development Center Americas, Deerfield, Illinois, USA
    Int Clin Psychopharmacol 29:36-44. 2014
    ..2 at week 52 (from 17.6 at open-label baseline) in the observed case data set. ..
  4. doi request reprint A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder
    Atul R Mahableshwarkar
    CNS Medicine, Takeda Development Center Americas, Deerfield, Illinois
    J Clin Psychiatry 76:583-91. 2015
    ..The mechanism of action of vortioxetine is thought to be related to direct modulation of serotonin (5-HT) receptor activity and inhibition of the serotonin transporter...
  5. doi request reprint A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder
    Paula L Jacobsen
    Takeda Development Center Americas, Deerfield, Illinois
    J Clin Psychiatry 76:575-82. 2015
    ..Vortioxetine (Lu AA21004) is an antidepressant with a mechanism of action thought to be related to a combination of 2 pharmacologic actions: direct modulation of several receptors and inhibition of the serotonin transporter...
  6. doi request reprint Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
    Paula L Jacobsen
    Takeda Development Center Americas, Deerfield, IL, USA
    J Sex Med 12:2036-48. 2015
    ..Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials...
  7. doi request reprint A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
    Atul R Mahableshwarkar
    Takeda Development Center Americas, Deerfield, Illinois, USA
    Hum Psychopharmacol 29:64-72. 2014
    ..Vortioxetine is a recently approved multimodal antidepressant with anxiolytic properties in preclinical studies...
  8. doi request reprint Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
    Paula L Jacobsen
    aTakeda Development Center Americas Inc, Deerfield, Illinois bCNS Healthcare, Orlando, Florida, USA
    Int Clin Psychopharmacol 30:255-64. 2015
    ..After entry into this study, patients continued to show improvement in depression and anxiety symptoms, as well as overall functioning, throughout the treatment period. ..
  9. doi request reprint A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
    Atul R Mahableshwarkar
    Takeda Development Center Americas, Deerfield, IL, USA
    Neuropsychopharmacology 40:2025-37. 2015
    ..In this study of MDD adults who self-reported cognitive dysfunction, vortioxetine significantly improved cognitive function, depression, and functionality and was generally well tolerated...